Myriad Genetics Overview
Myriad Genetics Target Price
Analysts' 12-month price predictions for MYGN.
Share Price
$5.09
Average Target Price
$11.00
116.1% upside
116.1% upside5 analysts in the last 4 months
High: $18 | Low: $6
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2025-05-07 | Craig-HallumBill Bonello | $18 | 253.6% upside |  |
| 2025-05-07 | UBSLu Li | $7 | 37.5% upside | |
| 2025-05-07 | Wells FargoBrandon Couillard | $6 | 17.9% upside | |
| 2025-03-12 | Piper Sandler | $12.5 | 145.6% upside | |
| 2025-03-04 | Piper Sandler | $11.5 | 125.9% upside | |
| 2024-12-09 | Leerink PartnersPuneet Souda | $21 | 312.6% upside | |
| 2024-10-14 | ScotiabankSung Ji Nam | $34 | 568% upside | |
| 2024-09-19 | Morgan StanleyTejas Savant | $32 | 528.7% upside | |
| 2024-08-27 | Wells FargoBrandon Couillard | $35 | 587.6% upside | |
| 2024-08-07 | GuggenheimSubbu Nambi | $29 | 469.7% upside | |
| 2024-06-26 | ScotiabankSung Ji Nam | $29 | 469.7% upside | |
| 2024-05-13 | Piper SandlerJon Peterson | $28 | 450.1% upside | |
| 2023-12-21 | Piper SandlerDavid Westenberg | $23 | 351.9% upside | |
| 2022-10-05 | StephensMason Carrico | $22 | 332.2% upside | |
| 2022-04-19 | Goldman Sachs | $23 | 351.9% upside | |